PAVmed (NASDAQ:PAVM – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.02 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
PAVmed Stock Performance
PAVM stock opened at $0.81 on Monday. The company’s fifty day moving average price is $0.69 and its 200-day moving average price is $0.92. PAVmed has a one year low of $0.57 and a one year high of $2.84. The company has a market capitalization of $8.97 million, a PE ratio of -0.19 and a beta of 1.19.
Analyst Ratings Changes
Separately, Ascendiant Capital Markets decreased their price target on shares of PAVmed from $21.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th.
PAVmed Company Profile
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Recommended Stories
- Five stocks we like better than PAVmed
- Transportation Stocks Investing
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 ETFs to Ride the VIX Surge During Market Volatility
- What is a Special Dividend?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.